Helen S. Kim is a Senior Managing Director at Vida Ventures.

​

Ms. Kim has more than 27 years of experience in leadership roles in biotechnology. Most recently, she was a partner at The Column Group. Prior to that, Ms. Kim served as Executive Vice President of Business Development at Kite Pharma where she led all business and corporate development initiatives culminating with the sale of Kite Pharma to Gilead Sciences in 2017.

​

Previously, Ms. Kim served as Strategic Advisor of NGM Biopharmaceuticals from January 2012 through November 2014. She served as the Chief Business Officer at NGM Biopharmaceuticals from August 2009 to January 2012. Prior to NGM, she was the Chief Executive Officer and President of Kosan Biosciences, where she restructured and repositioned the company prior to successfully selling it to Bristol-Myers Squibb in 2008. Ms. Kim’s additional industry experience includes executive positions at Affymax, Onyx Pharmaceuticals and Chiron Corporation. Ms. Kim received a BS in chemical engineering from Northwestern University and an MBA from the University of Chicago.

​

She currently serves on the board of directors of Peloton Therapeutics, Assembly Biosciences, Applied Molecular Transport, and Exicure.